What a journey you've been on — and it's genuinely encouraging to hear your health has significantly improved. That matters enormously, whatever the cause.
This is a really important question: should you stay on eplontersen (injections) or switch to an oral tablet like tafamidis or acoramidis for wild-type ATTR Show Full Answer
What a journey you've been on — and it's genuinely encouraging to hear your health has significantly improved. That matters enormously, whatever the cause.
This is a really important question: should you stay on eplontersen (injections) or switch to an oral tablet like tafamidis or acoramidis for wild-type ATTR cardiomyopathy (ATTRw-CM)? Here's a helpful breakdown of the approved oral options for ATTRw-CM:
- Tafamidis (Vyndamax) — once daily tablet, long-term data shows improved heart function and survival
- Acoramidis (Attruby) — twice daily tablet, a phase 3 study showed a 49% reduction in cardiovascular death or repeat hospitalizations
- Vutrisiran (Amvuttra) — subcutaneous injection every 3 months (not monthly)
All three are FDA-approved for ATTRw-CM, and specialists stress that none is clearly superior to another — they work differently but are all considered strong options. Since your doctors confirm there's no head-to-head evidence proving eplontersen is better or worse than the tablets, a few practical considerations worth discussing with your care team include:
- Your improvement — if your health has genuinely improved since June 2024 on eplontersen, that's a meaningful signal worth weighing carefully
- Cost — €/DKK 30,000 for acoramidis is a serious barrier, and that financial stress itself can affect wellbeing
- Convenience — monthly injections vs. daily tablets is a real lifestyle factor
- Early treatment benefit — research consistently shows that starting and *staying* on treatment early matters most for long-term outcomes One specialist's perspective worth keeping in mind: *"The only wrong option is to be on none of them."* Given that eplontersen is currently free and you're responding well, continuing it while monitoring closely seems like a very reasonable path — unless your doctors identify a specific clinical reason to switch.
Pushing your doctors for a more detailed comparison based on your specific heart function markers and progression rate would be a smart next step. You deserve a personalized answer, not just a general one.
7 days ago
Join
Your Privacy Choices
